Skip to main content
MDGL logo

MDGL · Madrigal Pharmaceuticals, Inc.

Track MDGL — free
$507.56 +0.19 (+0.04%) At close · Aug 14
Market Cap
$11.73B
Shares
23.10M

Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.

Filed Seller Shares
2026-06-01 DAVID SOERGEL 1,042
2026-05-22 RICHARD LEVY 5,682
2026-03-06 Mardi Dier 646
2026-03-06 Rebecca Taub 491
2026-03-06 William Sibold 1,663
2026-03-06 MARDI DIER 1,336
2026-03-06 Carole Huntsman 419
2026-03-06 Shannon Kelley 360
2026-03-02 Mardi Dier 1,183
2026-01-26 Rebecca Taub 647
2026-01-26 CAROLE A HUNTSMAN 570
2026-01-26 William Sibold 1,577
2026-01-26 Carole Huntsman 340
2026-01-20 Shannon Kelley 263
2026-01-20 SHANNON KELLEY 429
2026-01-20 Rebecca Taub 2,238
2026-01-09 REBECCA A TAUB 18,650
2025-12-10 PAUL FRIEDMAN 49,600
2025-12-10 REBECCA A TAUB 18,650
2025-12-04 William John Sibold 2,400
2025-12-02 MARDI C DIER 4,173
2025-11-21 Carole Huntsman 894
2025-11-13 RICHARD S LEVY 8,500
2025-11-05 KENNETH M BATE 16,575
2025-09-09 William John Sibold 7,279
2025-08-29 FRED CRAVES 2,900
2025-08-21 WILLIAM SIBOLD 7,616
2025-08-20 FRED CRAVES 1,000
2025-08-18 Shannon Kelley 458
2025-08-18 FRED CRAVES 2,000
2025-08-15 FRED CRAVES 4,100
2025-08-15 KENNETH M BATE 10,000
2025-08-13 PAUL FRIEDMAN 129,172
2025-08-12 PAUL FRIEDMAN 43,605
2025-08-12 REBECCA TAUB 43,263
2025-08-11 PAUL FRIEDMAN 3,203
2025-08-11 REBECCA TAUB 3,200
2025-07-18 PAUL FRIEDMAN 1,400
2025-07-18 REBECCA TAUB 1,000
2025-07-17 PAUL FRIEDMAN 2,700
2025-07-17 REBECCA TAUB 2,657
2025-07-16 REBECCA TAUB 26,444
2025-07-16 PAUL FRIEDMAN 26,176
2025-03-13 FRED CRAVES 7,742
2025-03-12 FRED CRAVES 7,428
2025-03-05 ROBERT WALTERMIRE 14,113
2025-03-03 Mardi Dier 1,187
2025-03-03 SHANNON KELLEY 415
2025-03-03 CAROLE A HUNTSMAN 1,834
2025-02-28 ROBERT WALTERMIRE 1,227
Showing 1–50 of 79 filings
Key facts CIK 1157601 CUSIP 558868105 13F (30d) 386 filings 383 filers Visit website Investor relations